Detalhe da pesquisa
1.
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Gynecol Oncol
; 185: 186-193, 2024 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447347
2.
Is there a role for secondary debulking in ovarian cancer? A review of the current literature.
Curr Opin Obstet Gynecol
; 35(1): 1-5, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36239548
3.
Advances in antibody-drug conjugates for gynecologic malignancies.
Curr Opin Obstet Gynecol
; 35(1): 6-14, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36484278
4.
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Gynecol Oncol
; 166(2): 219-229, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690498
5.
Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?
Gynecol Oncol
; 156(3): 568-574, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31948730
6.
Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
Int J Gynecol Cancer
; 30(11): 1738-1747, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32771986
7.
Olaparib in the treatment of ovarian cancer.
Future Oncol
; 15(30): 3435-3449, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31478762
8.
The emerging use of antibody-drug conjugates in ovarian cancer.
Clin Adv Hematol Oncol
; 21(5): 244-246, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37145494
9.
Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 146(3): 477-483, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28756871
10.
Should we or should we not? Secondary debulking in ovarian cancer.
Lancet Oncol
; 22(4): 412-413, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33705694
11.
Factors influencing primary treatment of midline vulvar cancers.
Gynecol Oncol
; 142(1): 133-138, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27132089
12.
Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.
Gynecol Oncol
; 136(1): 3-7, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25238946
13.
Ovarian involvement in endometrioid adenocarcinoma of uterus.
Gynecol Oncol
; 138(3): 532-5, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26186908
14.
Outcomes of Treatment of Gestational Trophoblastic Neoplasia in a Primarily Indigent Urban Population.
J Reprod Med
; 60(5-6): 243-8, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26126310
15.
Malignant ovarian germ cell tumor - role of surgical staging and gonadal dysgenesis.
Gynecol Oncol
; 134(1): 84-9, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24836278
16.
Factors associated with clinical trial screening failures in gynecologic oncology.
Gynecol Oncol
; 134(3): 450-4, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24992676
17.
Adnexal masses requiring surgical intervention in women with advanced cervical cancer.
Gynecol Oncol
; 134(3): 552-5, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25014542
18.
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Clin Ther
; 46(3): 228-238, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38423866
19.
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Int J Gynecol Cancer
; 23(5): 833-8, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23640292
20.
Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology.
Gynecol Oncol Rep
; 46: 101148, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37033209